> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novo Nordisk CEO Won't Guide For 2027, But Lists Three Pluses And Three Minuses
- URL: https://www.bullished.co/novo-nordisk-ceo-wont-guide-for-2027-but-lists-three-pluses-and-three-minuses-3ada6de1/
- Published: 2026-11-04T15:34:09.000Z
- Updated: 2026-11-04T15:34:09.000Z
- Description: Mike Doustdar gave analysts "building blocks" for next year as CFO Karsten Munk Knudsen announced his exit after 27 years.
- Author: Matteo Parrino
- Tags: Earnings, NVO, Industry: Healthcare

[Novo Nordisk](https://www.bullished.co/tag/nvo/) CEO Mike Doustdar refused to guide for 2027 on the company's [earnings call](https://finance.yahoo.com/markets/article/novo-nordisk-ceo-wegovy-pill-exceeded-our-expectations-141435213.html?ref=bullished.co) Wednesday, then handed analysts three positives and three negatives to model it themselves. The same call announced that CFO Karsten Munk Knudsen is leaving after 27 years.

## Three pluses, three minuses

Novo, the Danish maker of obesity, diabetes and rare-disease drugs including Ozempic and Wegovy, has raised its 2026 outlook to adjusted sales growth of minus 2% to plus 2%. Asked by a BNP Paribas analyst whether a positive growth number could appear in February guidance, Doustdar said "we're not going to guide" but promised to "go out of my way and provide even more building blocks" so analysts could do their own math.

The pluses: continued Wegovy pill uptake in the US and internationally; the US bridge program, which he said started mid-year and so must be annualized; and two launches, CagriSema in the US and Frehemgo on both sides of the Atlantic.

The minuses: loss of semaglutide exclusivity in international markets, which showed up more in the third quarter than the second; a continued drag in China, where exclusivity is also lost next year; and favorable gross-to-net in 2026 that he said Novo should not expect "to the same degree" next year.

## Which baseline for next year

Analysts at Bank of America and UBS asked whether the mid-single-digit growth of the second and third quarters or the 0% guidance midpoint is the better proxy. Doustdar would not pick, saying the midpoint is how Novo will look at it going forward.

Third-quarter adjusted sales rose 4% to DKK 79.2 billion, and adjusted operating profit rose 27%, CFO Knudsen said. Doustdar said sales fell 2% in the fourth quarter of 2025 and 4% in the first quarter of 2026 before growth of 7% and 4% in the next two quarters.

## The bridge program carries the pill

US operations EVP Jamey Millar said the Wegovy pill's roughly 20% sequential volume growth was "largely but not exclusively" bridge volume, with about 60,000 weekly prescriptions across injectable and oral. Excluding bridge, he said, the whole weight-loss category looked relatively flat from May to October.

Responding to a Jefferies analyst, he said that without bridge there would be less growth than 20%. Asked about Medicare coverage after the program ends, Millar said it is hard to predict the political environment at the end of 2027.

## A CFO handoff

Doustdar said Luigi La Corte, currently CFO of Galderma, will join as incoming CFO. Knudsen, [CFO for the past nine years](https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits?ref=bullished.co), stays through year-end.

Novo will give 2027 guidance with its full-year announcement, Doustdar said. EVP Millar said the company looks forward to potential FDA approval of the Ozempic pill 25 milligrams by the end of the year.

Doustdar's own summary of the setup: the bridge program is "a great example" of a positive, while loss of exclusivity in international operations is "exactly the opposite."

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Novo Nordisk CEO: Wegovy pill 'exceeded our expectations'](https://finance.yahoo.com/markets/article/novo-nordisk-ceo-wegovy-pill-exceeded-our-expectations-141435213.html?ref=bullished.co) — Yahoo Finance
- [Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines](https://www.benzinga.com/markets/earnings/26/11/62863179/novo-nordisk-raises-2026-outlook-as-wegovy-pill-shines?ref=bullished.co) — benzinga.com
- [Novo Nordisk lifts outlook on obesity drug sales](https://finance.yahoo.com/healthcare/articles/novo-nordisk-lifts-outlook-obesity-091837754.html?ref=bullished.co) — Yahoo Finance
- [Novo aims for deals to ‘close some gaps’ as misfires hit profits](https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits?ref=bullished.co) — fiercebiotech.com
- [Novo Nordisk hikes 2026 outlook again](https://www.rte.ie/news/business/2026/1104/1597924-novo-nordisk-quarterly-results/?ref=bullished.co) — rte.ie

### More on Novo Nordisk

- [Novo Nordisk Stock Surges 6% After It Raises 2026 Outlook On Obesity Drug Sales](https://www.bullished.co/novo-nordisk-stock-surges-6-after-it-raises-2026-outlook-on-obesity-drug-sales-f75594ee/)
- [Novo Nordisk Raises 2026 Outlook As Adjusted Operating Profit Climbs 27% On Wegovy Pill Sales](https://www.bullished.co/novo-nordisk-raises-2026-outlook-as-adjusted-operating-profit-climbs-27-on-wegovy-pill-7e313ec8/)

[All Novo Nordisk (NVO) coverage →](https://www.bullished.co/tag/nvo/)